Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: A pilot study

Mai Kimura, Yuichi Tamura, Makoto Takei, Tsunehisa Yamamoto, Tomohiko Ono, Jun Fujita, Masaharu Kataoka, Masataka Kuwana, Toru Satoh, Keiichi Fukuda

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Background: Recent vasodilating drugs have improved prognosis of Pulmonary arterial hypertension (PAH). Some reports describe the merits of combination therapies for PAH, and this study evaluated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5i) combination therapy, using sildenafil and tadalafil, for multi-drug-resistant PAH. Methods: We retrospectively analyzed 7 consecutive refractory patients with PAH administered either sildenafil 60 mg or tadalafil 40 mg as well as both ERA and prostanoid as combination therapies. All were started on the dual PDE5i (sildenafil and tadalafil at maximum dose). Results: Treatment was generally well tolerated without severe adverse events. On completion of the study, the seven patients received right heart catheterization and the 6-minute walk test (6WMT) 9.6 ± 1.4 months after initiation of the dual PDE5i therapy, showing significant improvements in hemodynamic parameters and exercise tolerance. Mean pulmonary arterial pressure and pulmonary vascular resistance decreased from 47.9 ± 9.7 to 41.7 ± 9.2 mmHg (P = 0.004) and 9.3 ± 2.7 to 6.7 ± 2.9 mmHg (P = 0.018), respectively. Cardiac index and 6MWT also increased from 2.8 ± 0.9 to 3.1 ± 0.8 L/min/m2 (P = 0.026) and 353 ± 60 to 382 ± 62 m (P = 0.014), respectively. Conclusion: The findings support dual PDE5i therapy as a new treatment option for refractory PAH.

Original languageEnglish
Article number62
JournalBMC Pulmonary Medicine
Volume15
Issue number1
DOIs
Publication statusPublished - 2015 May 14

Keywords

  • New treatment option
  • Phosphodiesterase type 5 inhibitor
  • Pulmonary arterial hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: A pilot study'. Together they form a unique fingerprint.

Cite this